| Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies BC Bernardo, KL Weeks, L Pretorius, JR McMullen Pharmacology & therapeutics 128 (1), 191-227, 2010 | 1138 | 2010 |
| Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets YK Tham, BC Bernardo, JYY Ooi, KL Weeks, JR McMullen Archives of toxicology 89, 1401-1438, 2015 | 733 | 2015 |
| The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? KL Weeks, JR McMullen Physiology 26 (2), 97-105, 2011 | 243 | 2011 |
| Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin CE Winbanks, KL Weeks, RE Thomson, PV Sepulveda, C Beyer, H Qian, ... Journal of Cell Biology 197 (7), 997-1008, 2012 | 228 | 2012 |
| PI3K (p110α) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA RCY Lin, KL Weeks, XM Gao, RBH Williams, BC Bernardo, H Kiriazis, ... Arteriosclerosis, thrombosis, and vascular biology 30 (4), 724-732, 2010 | 198 | 2010 |
| Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction KL Weeks, X Gao, XJ Du, EJH Boey, A Matsumoto, BC Bernardo, ... Circulation: Heart Failure 5 (4), 523-534, 2012 | 136 | 2012 |
| Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: current knowledge and emerging concepts BC Bernardo, JYY Ooi, KL Weeks, NL Patterson, JR McMullen Physiological Reviews 98 (1), 419-475, 2018 | 132 | 2018 |
| The IGF1-PI3K-Akt signaling pathway in mediating exercise-induced cardiac hypertrophy and protection KL Weeks, BC Bernardo, JYY Ooi, NL Patterson, JR McMullen Exercise for cardiovascular disease prevention and treatment: from molecular …, 2017 | 98 | 2017 |
| Histone deacetylases in cardiovascular and metabolic diseases RA Bagchi, KL Weeks Journal of Molecular and Cellular Cardiology 130, 151-159, 2019 | 79 | 2019 |
| Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction D Prakoso, MJ De Blasio, C Qin, S Rosli, H Kiriazis, H Qian, XJ Du, ... Clinical science 131 (12), 1345-1360, 2017 | 51 | 2017 |
| Adeno-associated virus gene therapy: translational progress and future prospects in the treatment of heart failure S Bass-Stringer, BC Bernardo, CN May, CJ Thomas, KL Weeks, ... Heart, Lung and Circulation 27 (11), 1285-1300, 2018 | 43 | 2018 |
| Roles and post‐translational regulation of cardiac class IIa histone deacetylase isoforms KL Weeks, M Avkiran The Journal of physiology 593 (8), 1785-1797, 2015 | 38 | 2015 |
| Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes D Prakoso, MJ De Blasio, M Tate, H Kiriazis, DG Donner, H Qian, D Nash, ... American Journal of Physiology-Heart and Circulatory Physiology 318 (4 …, 2020 | 35 | 2020 |
| β‐Adrenergic Stimulation Induces Histone Deacetylase 5 (HDAC 5) Nuclear Accumulation in Cardiomyocytes by B55α‐PP 2A‐Mediated Dephosphorylation KL Weeks, A Ranieri, A Karaś, BC Bernardo, AS Ashcroft, C Molenaar, ... Journal of the American Heart Association 6 (4), e004861, 2017 | 33 | 2017 |
| HSP70: therapeutic potential in acute and chronic cardiac disease settings BC Bernardo, KL Weeks, NL Patterson, JR McMullen Future medicinal chemistry 8 (18), 2177-2183, 2016 | 25 | 2016 |
| Glycogen-autophagy: Molecular machinery and cellular mechanisms of glycophagy P Koutsifeli, U Varma, LJ Daniels, M Annandale, X Li, JPH Neale, ... Journal of Biological Chemistry 298 (7), 2022 | 24 | 2022 |
| Assessing structural and functional responses of murine hearts to acute and sustained β-adrenergic stimulation in vivo SL Puhl, KL Weeks, A Ranieri, M Avkiran Journal of pharmacological and toxicological methods 79, 60-71, 2016 | 24 | 2016 |
| Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling BC Bernardo, KL Weeks, T Pongsukwechkul, X Gao, H Kiriazis, ... Clinical Science 132 (3), 381-397, 2018 | 23 | 2018 |
| FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K KL Weeks, YK Tham, SG Yildiz, Y Alexander, DG Donner, H Kiriazis, ... American Journal of Physiology-Heart and Circulatory Physiology 320 (4 …, 2021 | 20 | 2021 |
| CORP: Practical tools for improving experimental design and reporting of laboratory studies of cardiovascular physiology and metabolism KL Weeks, DC Henstridge, A Salim, JE Shaw, TH Marwick, JR McMullen American Journal of Physiology-Heart and Circulatory Physiology 317 (3 …, 2019 | 12 | 2019 |
Dr Bianca C. BernardoGroup Leader. Baker Heart and Diabetes Institute, Melbourne, AustraliaVerified email at bakeridi.edu.au
